Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: Evidence from genetically modified mouse models and pharmacological inhibition

Biochemical Pharmacology

Volumn 81, Issue 9, 2011, Pages 1065-1077

  Möhler, Hanns ^a   Boison, Detlev ^b   Singer, Philipp ^a   Feldon, Joram ^a   Pauly Evers, Meike ^c   Yee, Benjamin K ^a  

^a ETH ZURICH   (Switzerland)

^b LEGACY RESEARCH   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antipsychotic; Attention; Cognition; Learning; NMDA

Indexed keywords

GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

BRAIN FUNCTION; DRUG ACTIVITY; DRUG TARGETING; FOREBRAIN; HUMAN; LEARNING; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRANSGENIC MOUSE; WORKING MEMORY;

EID: 79953683678     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.02.003     Document Type: Note

References (134)

1. S.H. Snyder Catecholamines in the brain as mediators of amphetamine psychosis Arch Gen Psychiatry 27 1972 169 179
2. D.A. Lewis, J.N. Pierri, D.W. Volk, D.S. Melchitzky, and T.U. Woo Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia Biol Psychiatry 46 1999 616 626 (Pubitemid 29401859)
3. D.A. Lewis, T. Hashimoto, and D.W. Volk Cortical inhibitory neurons and schizophrenia Nat Rev Neurosci 6 2005 312 324 (Pubitemid 40469985)
4. D.A. Lewis, R.Y. Cho, C.S. Carter, K. Eklund, S. Forster, and M.A. Kelly Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia Am J Psychiatry 165 2008 1585 1593
5. D.A. Lewis, and T. Hashimoto Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons Int Rev Neurobiol 78 2007 109 131
6. D.C. Javitt Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia Hillside J Clin Psychiatry 9 1987 12 35
7. D.C. Javitt Glutamatergic theories of schizophrenia Isr J Psychiatry Relat Sci 47 2010 4 16
8. J.W. Olney, J.W. Newcomer, and N.B. Farber NMDA receptor hypofunction model of schizophrenia J Psychiatr Res 33 1999 523 533
9. N.B. Farber The NMDA receptor hypofunction model of psychosis Ann NY Acad Sci 1003 2003 119 130 (Pubitemid 38083050)
10. T.V. Bliss, and G.L. Collingridge A synaptic model of memory: long-term potentiation in the hippocampus Nature 361 1993 31 39 (Pubitemid 23020772)
11. G.L. Collingridge, and T.V. Bliss Memories of NMDA receptors and LTP Trends Neurosci 18 1995 54 56
12. G. Gonzalez-Burgos, T. Hashimoto, and D.A. Lewis Alterations of cortical GABA neurons and network oscillations in schizophrenia Curr Psychiatry Rep 12 2010 335 344
13. G. Gonzalez-Burgos, and D.A. Lewis GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia Schizophr Bull 34 2008 944 961
14. D.W. Volk, J.N. Pierri, J.M. Fritschy, S. Auh, A.R. Sampson, and D.A. Lewis Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia Cereb Cortex 12 2002 1063 1070
15. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell Mol Neurobiol 26 2006 365 384
16. G.J. Marek, B. Behl, A.Y. Bespalov, G. Gross, Y. Lee, and H. Schoemaker Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77 2010 317 326
17. D.C. Javitt Glycine transport inhibitors and the treatment of schizophrenia Biol Psychiatry 63 2008 6 8 (Pubitemid 350234898)
18. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, and R.P. McMahon The cognitive and negative symptoms in Schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 2007 1593 1602 (Pubitemid 350069740)
19. F. Zafra, C. Aragon, L. Olivares, N.C. Danbolt, C. Gimenez, and J. Storm-Mathisen Glycine transporters are differentially expressed among CNS cells J Neurosci 15 1995 3952 3969
20. G. Tsai, R.J. Ralph-Williams, M. Martina, R. Bergeron, J. Berger-Sweeney, and K.S. Dunham Gene knockout of glycine transporter 1: characterization of the behavioural phenotype Proc Natl Acad Sci USA 101 2004 8485 8490 (Pubitemid 38736601)
21. H.Y. Lane, Y.C. Chang, Y.C. Liu, C.C. Chiu, and G.E. Tsai Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study Arch Gen Psychiatry 62 2005 1196 1204 (Pubitemid 41586919)
22. H.Y. Lane, C.L. Huang, P.L. Wu, Y.C. Liu, Y.C. Chang, and P.Y. Lin Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia Biol Psychiatry 160 2006 645 649
23. H.Y. Lane, C.H. Lin, Y.J. Huang, C.H. Liao, Y.C. Chang, and G.E. Tsai A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia Int J Neuropsychopharmacol 13 2010 451 460
24. H.Y. Lane, Y.C. Liu, C.L. Huang, Y.C. Chang, C.H. Liau, and C.H. Perng Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study Biol Psychiatry 63 2008 9 12
25. D.C. Javitt, L. Duncan, A. Balla, and H. Sershen Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action Mol Psychiatry 10 2005 275 287
26. G.E. Tsai, and P.Y. Lin Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis Curr Pharm Des 16 2010 522 537
27. E. Pinard, A. Alanine, D. Alberati, M. Bender, E. Borroni, and P. Bourdeaux Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia J Med Chem 53 2010 4603 4614
28. J. Gomeza, S. Hulsmann, K. Ohno, V. Eulenburg, K. Szoke, and D. Richter Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition Neuron 40 2003 785 796 (Pubitemid 37431038)
29. J. Gomeza, K. Ohno, S. Hulsmann, W. Armsen, V. Eulenburg, and D.W. Richter Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality Neuron 40 2003 797 806 (Pubitemid 37431039)
30. M.M.E. Martina, B.T. Halman, S. Tsai, G. Tiberi, M. Tiberi, and J.T. Coyle Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice J Physiol 563 2005 777 793 (Pubitemid 40425594)
31. L. Gabernet, M. Pauly-Evers, C. Schwerdel, M. Lentz, H. Bluethmann, and K. Vogt Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression Neurosci Lett 373 2005 79 84 (Pubitemid 39536225)
32. C. Schweizer, S. Balsiger, H. Bluethmann, I.M. Mansuy, J.M. Fritschy, and H. Mohler The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses Mol Cell Neurosci 24 2003 442 450 (Pubitemid 37311307)
33. B.K. Yee, E. Balic, P. Singer, C. Schwerdel, T. Grampp, and L. Gabernet Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile J Neurosci 26 2006 3169 3181
34. T. Iwasato, R. Nomura, R. Ando, T. Ikeda, M. Tanaka, and S. Itohara Dorsal telencephalon-specific expression of Cre recombinase in PAC transgenic mice Genesis 38 2004 130 138 (Pubitemid 38506850)
35. P. Singer, B.K. Yee, J. Feldon, T. Iwasato, S. Itohara, and T. Grampp Altered mnemonic functions and resistance to N-methyl-d-aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1 Neuroscience 161 2009 635 654
36. Y. Zhu, M.I. Romero, P. Ghosh, Z. Ye, P. Charnay, and E.J. Rushing Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain Genes Dev 15 2001 859 876 (Pubitemid 32295067)
37. V. Eulenburg, M. Retiounskaia, T. Papadopoulos, J. Gomeza, and H. Betz Glial glycine transporter 1 function is essential for early postnatal survival but dispensable in adult mice Glia 58 2010 1066 1073
38. S. Marino, M. Vooijs, H. van Der Gulden, J. Jonkers, and A. Berns Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum Genes Dev 14 2000 994 1004 (Pubitemid 30253007)
39. P. Singer, D. Boison, H. Möhler, J. Feldon, and B.K. Yee Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons Behav Neurosci 121 2007 815 825 (Pubitemid 350051286)
40. P. Singer, D. Boison, H. Möhler, J. Feldon, and B.K. Yee Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability? Behav Neurosci 123 2009 1012 1027
41. Singer P, Boison D, Möhler H, Feldon J, Yee BK. Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice. Eur Neuropsychopharmacol; in press (PMCID: PMC2980791).
42. S. Dubroqua, P. Singer, D. Boison, J. Feldon, H. Mohler, and B.K. Yee Impacts of forebrain neuronal glycine transporter 1 disruption in the senescent brain: evidence for age-dependent phenotypes in Pavlovian learning Behav Neurosci 124 2010 839 850
43. D.M. Barch, and E. Smith The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia Biol Psychiatry 64 2008 11 17
44. J.X. Van Snellenberg Working memory and long-term memory deficits in schizophrenia: is there a common substrate? Psychiatry Res 174 2009 89 96
45. E. Kraepelin E. Barclay, S. Barclay, Dementia praecox 1919/1971 Churchill Livingstone Inc. New York
46. E. Bleuler Dementia praecox or the group of schizophrenias. German edition published in 1911 1950 International Universities Press New York
47. D. Braff, M.A. Geyer, and N.R. Swerdlow Sensorimotor gating and schizophrenia: human and animal model studies Arch Gen Psychiatry 47 2001 181 188
48. Braff Dl, C. Grillon, and M.A. Geyer Gating and habituation of the startle reflex in schizophrenic patients Arch Gen Psychiatry 49 1992 206 215
49. N.S. Gray, D.R. Hemsley, and J.A. Gray Abolition of latent inhibition in acute, but not chronic, schizophrenics Neurol Psychiatry Brain Res 1 1992 83 89 (Pubitemid 24025553)
50. C. Rascle, O. Mazas, G. Vaiva, M. Tournant, O. Raybois, and M. Goudemand Clinical features of latent inhibition in schizophrenia Schizophr Res 51 2001 149 161 (Pubitemid 32772848)
51. N.R. Swerdlow, D.L. Braff, N. Taaid, and M.A. Geyer Assessing the validity of an animal model of deficient sensorimotor gating inschizophrenia patients Arch Gen Psychiatry 51 1994 139 154 (Pubitemid 24985903)
52. J.H. Williams, N.A. Wellman, D.P. Geaney, P.J. Cowen, J. Feldon, and J.N.P. Rawlins Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment Br J Psychiatry 172 1998 243 249 (Pubitemid 28123115)
53. B.I. Turetsky, M.E. Calkins, G.A. Light, A. Olincy, A.D. Radant, and N.R. Swerdlow Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures Schizophr Bull 33 2007 69 94 (Pubitemid 46026260)
54. V. Kumari, M. Das, E. Zachariah, U. Ettinger, and T. Sharma Reduced prepulse inhibition in unaffected siblings of schizophrenia patients Psychophysiology 42 2005 588 594 (Pubitemid 43942839)
55. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology (Berl) 156 2001 117 154 (Pubitemid 32702206)
56. N.R. Swerdlow, M. Weber, Y. Qu, G.A. Light, and D.L. Braff Realistic expectations of prepulse inhibition in translational models for schizophrenia research Psychopharmacology (Berl) 9 2008 331 388
57. I. Weiner, and M. Arad Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment Behav Brain Res 204 2009 369 386
58. R.E. Lubow, and A.U. Moore Latent inhibition: the effect of nonreinforced preexposure to the conditional stimulus J Comp Physiol Psychol 66 1959 688 694
59. F. Graham The more or less startling effects of weak prestimulation Psychophysiology 12 1975 238 248
60. H.S. Hoffman, and J.L. Searle Acoustic variables in the modification of startle reaction in the rat J Comp Physiol Psychol 60 1965 53 58
61. I. Weiner Neural substrates of latent inhibition: the switching model Psychol Bull 108 1990 442 461
62. D. Boulay, P. Pichat, G. Dargazanli, G. Estenne-Bouhtou, J.P. Terranova, and N. Rogacki 103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia Pharmacol Biochem Behav 91 2008 47 58
63. T.E. Robinson, and J.B. Becker Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis Brain Res 396 1986 157 159
64. M. Laruelle The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies Brain Res Brain Res Rev 31 2000 371 378
65. J.A. Pratt, C. Winchester, A. Egerton, S.M. Cochran, and B.J. Morris Modelling prefrontal cortex deficits in schizophrenia: implications for treatment Br J Pharmacol 153 March (Suppl. 1) 2008 S465 S470
66. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004;174:111-25.
67. U. Meyer, J. Feldon, M. Schedlowski, and B.K. Yee Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia Neurosci Biobehav Rev 29 2005 913 947 (Pubitemid 41097394)
68. U. Meyer, J. Feldon, and B.K. Yee A review of the fetal brain cytokine imbalance hypothesis of schizophrenia Schizophr Bull 35 2009 959 967
69. S. Pietropaolo, P. Singer, J. Feldon, and B.K. Yee The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex Psychopharmacology 197 2008 613 628
70. M. Niwa, Y. Matsumoto, A. Mouri, N. Ozaki, and T. Nabeshima Vulnerability in early life to changes in the rearing environment plays a crucial role in the aetiopathology of psychiatric disorders Int J Neuropsychopharmacol 18 2010 1 19
71. D.C. Javitt, H. Sershen, A. Hashim, and A. Lajtha Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide Neuropsychopharmacology 17 1997 202 204 (Pubitemid 27365961)
72. D.C. Javitt, and M. Frusciante Glycyldodecylamide, a phencyclidine behavioural antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse Psychopharmacology (Berl) 129 1997 96 98 (Pubitemid 27037457)
73. T.M. Bridges, R. Williams, and C.W. Lindsley Design of potent GlyT1 inhibitors: in vitro and in vivo profiles Curr Opin Mol Ther 10 2008 591 601
74. K. Hashimoto Glycine transporter inhibitors as therapeutic agents for schizophrenia Recent Pat CNS Drug Discov 1 2006 43 53
75. D.C. Javitt Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification Curr Opin Drug Discov Dev 12 2009 468 478
76. P. Singer, J. Feldon, and B.K. Yee Interference of glycine transporter 1: modulation of cognitive functions via activation of glycine-B site of the NMDA receptor CNS Agents Med Chem 7 2007 259 268 (Pubitemid 350291651)
77. R. Depoortre, G. Dargazanli, G. Estenne-Bouhtou, A. Coste, C. Lanneau, and C. Desvignes Neurochemical electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 30 2005 1963 1985 (Pubitemid 43093498)
78. R. Bergeron, T.M. Meyer, J.T. Coyle, and R.W. Greene Modulation of N-methyl-d-aspartate receptor function by glycine transport Proc Natl Acad Sci USA 95 1998 15730 15734 (Pubitemid 29018768)
79. L. Chen, M. Muhlhauser, and C.R. Yang Glycine transporter-1blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo J Neurophysiol 89 2003 691 703 (Pubitemid 36206118)
80. G.G. Kinney, C. Sur, M. Burno, P.J. Mallorga, J.B. Williams, and D.J. Figueroa The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)- 3-(4′-phenylphenoxy) propyl] sarcosine potentiates NMDA receptor-mediated resposes in vivo and produces an antipsychotic profile in rodent behaviour J Neurosci 23 2003 7586 7591 (Pubitemid 37034075)
81. D. Alberati, J.L. Moreau, R. Mory, E. Pinard, and J.G. Wettstein Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential Pharmacol Biochem Behav 97 2010 185 191
82. M.E. Calkins, R.C. Gur, J.D. Ragland, and R.E. Gur Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives Am J Psychiatry 162 2005 1963 1966 (Pubitemid 41428629)
83. T. Shimazaki, A. Kaku, and S. Chaki d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats Psychopharmacology (Berl) 209 2010 263 270
84. P. Singer, J. Feldon, and B.K. Yee The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice Psychopharmacology (Berl) 202 2009 371 384
85. S.C. Mao, H.C. Lin, and P.W. Gean Augmentation of fear extinction by infusion of glycine transporter blockers into the amygdala Mol Pharmacol 76 2009 369 378
86. P. Singer, J. Feldon, and B.K. Yee Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour Eur Neuropsychopharmacol 19 2009 571 580
87. H. Nishikawa, T. Inoue, T. Izumi, S. Nakagawa, and T. Koyama A glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats Behav Pharmacol 21 2010 576 579 SSR504734
88. B.M. Roberts, C.L. Shaffer, P.A. Seymour, C.J. Schmidt, G.V. Williams, and S.A. Castner Glycine transporter inhibition reverses ketamine-induced working memory deficits Neuroreport 21 2010 390 394
89. D. Manahan-Vaughan, V. Wildförster, and C. Thomsen Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1) Eur J Neurosci 28 2008 1342 1350
90. S. Harich, G. Gross, and A. Bespalov Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment Psychopharmacology (Berl) 192 2007 511 519 (Pubitemid 46870746)
91. J. Karasawa, K. Hashimoto, and S. Chaki d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats Behav Brain Res 186 2008 78 83 (Pubitemid 350100896)
92. K. Hashimoto, Y. Fujita, T. Ishima, S. Chaki, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine Eur Neuropsychopharmacol 18 2008 414 421 (Pubitemid 351608551)
93. M.A. Geyer, and A. Markou The role of preclinical models in the development of psychotropic drugs K.L. Davis, D. Charney, J.T. Coyle, C.B. Nemeroff, Neuropsychopharmacology: the fifth generation of progress 2002 Lippincott, Williams and Wilkins 445 455
94. N.R. Swerdlow, D.L. Braff, and M.A. Geyer Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon Behav Pharmacol 11 2000 185 204 (Pubitemid 30449750)
95. T. Lipina, V. Labrie, I. Weiner, and J. Roder Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia Psychopharmacology (Berl) 179 2005 54 67 (Pubitemid 40576692)
96. R. Waziri, and S. Baruah A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings Schizophr Res 37 1999 205 225
97. U. Heresco-Levy, G. Bar, R. Levin, M. Ermilov, R.P. Ebstein, and D.C. Javitt High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients Schizophr Res 91 2007 14 21
98. I. Weiner, and J. Feldon The switching model of latent inhibition: an update of neural substrates Behav Brain Res 88 1997 11 25 (Pubitemid 27459688)
99. B.A. Ellenbroek, and A.R. Cools Animal models with construct validity for schizophrenia Behav Pharmacol 1 1990 469 490
100. J.A. Gray, J. Feldon, J.N.P. Rawlins, D.R. Hemsley, and A.D. Smith The neuropsychology of schizophrenia Behav Brain Sci 14 1991 1 84
101. P.C. Moser, J.M. Hitchcock, S. Lister, and P.M. Moran The pharmacology of latent inhibition as an animal model of schizophrenia Brain Res Rev 33 2000 275 307
102. I. Weiner The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment Psychopharmacology (Berl) 169 2003 257 297 (Pubitemid 37264944)
103. M.D. Black, G.B. Varty, M. Arad, S. Barak, A. De Levie, and D. Boulay Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat Psychopharmacology (Berl) 202 2009 385 396
104. G. Le Pen, J. Kew, D. Alberati, E. Borroni, M.P. Heitz, and J.L. Moreau Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor Biol Psychiatry 54 2003 1162 1170 (Pubitemid 37464862)
105. H.H. Chen, A. Stoker, and A. Markou The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice Psychopharmacology (Berl) 209 2010 343 350
106. K. Kopec, D.G. Flood, M. Gasior, B.A. McKenna, E. Zuvich, and J. Schreiber Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice Biochem Pharmacol 80 2010 1407 1417
107. S.Y. Yang, C.J. Hong, Y.H. Huang, and S.J. Tsai The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats Neurosci Lett 469 2010 127 130
108. C.R Yang, and K.A. Svensson Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia Pharmacol Ther 120 2008 317 332
109. K.W. Perry, J.F. Falcone, M.J. Fell, J.W. Ryder, H. Yu, and P.L. Love Neurochemical and behavioural profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas Neuropharmacology 55 2008 743 754
110. L.H. Zhang, N. Gong, D. Fei, L. Xu, and T.L. Xu Glycine uptake regulates hippocampal network activity via glycine receptormediated tonic inhibition Neuropsychopharmacology 33 2008 701 711
111. D. Rujescu, A. Bender, M. Keck, A.M. Hartmann, F. Ohl, and H. Raeder A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioural abnormalities Biol Psychiatry 59 2006 721 729
112. F Sams-Dodd Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats Neuropsychopharmacology 19 1998 18 25 (Pubitemid 28255210)
113. P.A. Arguello, and J.A. Gogos Modeling madness in mice: one piece at a time Neuron 52 2006 179 196 (Pubitemid 44466363)
114. M.A. Geyer, and B. Moghaddam Animal models relevant to schizophrenia disorders K.L. Davis, D.S. Charney, J.T. Coyle, C. Nemeroff, Neuropsychopharmacology: the fifth generation of progress 2002 Lippincott Williams and Wilkins Philadelphia 689 701
115. M. Leonetti, C. Desvignes, I. Bougault, J. Souilhac, F. Oury-Donat, and R. Steinberg 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3- trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission Neuroscience 137 2006 555 564 (Pubitemid 43031521)
116. B.M. Angrist, E. Peselow, M. Rubinstein, J. Corwin, and J. Rotrosen Partial improvement in negative schizophrenic symptoms after amphetamine Psychopharmacology (Berl) 78 1982 128 130 (Pubitemid 13234088)
117. D.M. Barch, and C.S. Carter Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers Schizophr Res 77 2005 43 58 (Pubitemid 40957060)
118. L.G. Harsing Jr., I. Gacsalyi, G. Szabo, E. Schmidt, N. Sziray, and C. Sebban The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study Pharmacol Biochem Behav 74 2003 811 825 (Pubitemid 36351646)
119. D. Boulay, O. Bergis, P. Avenet, and G. Griebel The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice Neuropsychopharmacology 35 2010 416 427
120. P.F. Buckley, B.J. Miller, D.S. Lehrer, and D.J. Castle Psychiatric comorbidities and schizophrenia Schizophr Bull 35 2009 383 402
121. H.J. Möller Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues World J Biol Psychiatry 6 2005 247 263
122. A. Molander, H.H. Lidö, E. Löf, M. Ericson, and B. Söderpalm The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats Alcohol Alcohol 42 2007 11 18 (Pubitemid 46062634)
123. V. Vengeliene, F. Leonardi-Essmann, W.H. Sommer, M. Marston, and H. Spanagel R. Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats Biol Psychiatry 68 2010 704 711
124. T. Dohi, K. Morita, T. Kitayama, N. Motoyama, and N. Morioka Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain Pharmacol Ther 123 2009 54 79
125. H. Hermanns, U. Muth-Selbach, R. Williams, S. Krug, P. Lipfert, and R. Werdehausen Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain Neurosci Lett 445 2008 214 219
126. K. Morita, N. Motoyama, T. Kitayama, N. Morioka, K. Kifune, and T. Dohi Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice J Pharmacol Exp Ther 326 2008 633 645
127. M. Tanabe, K. Takasu, S. Yamaguchi, D. Kodama, and H. Ono Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment Anesthesiology 108 2008 929 937 (Pubitemid 351589490)
128. M. Kalinichev, K.R. Starr, S. Teague, A.M. Bradford, R.A. Porter, and H.J. Herdon Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test Brain Res 1331 2010 105 113
129. K. Socała, D. Nieoczym, C. Rundfeldt, and P. Wlaź Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models Pharmacol Rep 62 2010 392 397
130. A. Gadea, and A.M. López-Colomé Glial transporters for glutamate, glycine, and GABA III. Glycine transporters J Neurosci Res 64 2001 218 222 (Pubitemid 32385689)
131. A. Gadea, and A.M. López-Colomé Glial transporters for glutamate, glycine and GABA I Glutamate transporters J Neurosci Res 63 2001 453 460 (Pubitemid 32193702)
132. T.X. Xu, N. Gong, and T.L. Xu Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission Neuroreport 16 2005 1227 1231 (Pubitemid 41058474)
133. M. Davis, K. Ressler, B.O. Rothbaum, and R. Richardson Effects of d-cycloserine on extinction: translation from preclinical to clinical work Biol Psychiatry 60 2006 369 375 (Pubitemid 44215855)
134. D.K. Walker, K.J. Ressler, K.-T. Lu, and M. Davis Facilitation of conditioned fear extinction by systemic administration or intra-amygdala Infusions of d-cycloserine as assessed with fear-potentiated startle in rats J Neurosci 22 2002 2343 2351 (Pubitemid 35386533)